MATR3 / Matrin-3 · Western blot design guide

Design a Western Blot for MATR3

Source-linked MATR3 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-MATR3 WB antibodies. Everything you need to plan the experiment before you commit precious samples.

Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for MATR3: expected band ~94.6 kDa, hero antibody A02931-2, catalog values and labelled standard workflow; separate PMC comparisons on the guide
Printable MATR3 Western blot protocol sheet — expected band ~94.6 kDa, antibody A02931-2, controls and PMC citations. Open the full MATR3 WB guide →

MATR3 Western Blot Experimental Design Guide

Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band ~94.6 kDa
Observed band ~125 kDa
Gel 5–20% (catalog A02931-2)
Positive control ⓘ Adipose tissue (IHC candidate; verify WB) +4 more
Negative control ⓘ Suggested KO / knockdown lysate
Important caveats
Reasons your observed band may differ from the expected size.
PTM Phosphorylated + Acetylated
Caveat Phosphorylation-state controls
Gene-set association MSigDB C7 membership
Isoform 2 isoform(s)
Section 1

Source-Linked MATR3 Western Blot Protocol Options

The A02931-2 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.

Recommended Western blot protocol parameters
Sample / lysatehuman MCF-7, human SH-SY5Y, human RT4, human HepG2, rat brain, mouse brain (catalog A02931-2)
Gel %5–20% (catalog A02931-2)
Load30 ug; reducing conditions (catalog A02931-2)
Transfera nitrocellulose membrane at 150 mA for 50-90 minutes (catalog A02931-2)
Membranenitrocellulose membrane (catalog A02931-2)
Blocking5% non-fat milk/TBS for 1.5 hour at RT (catalog A02931-2)
Primary antibodyA02931-2 · 0.25 μg/mL (catalog A02931-2)
Primary incubationovernight at 4°C (catalog A02931-2)
Secondary antibodygoat anti-rabbit IgG-HRP, 1:5000 (catalog A02931-2)
Secondary incubation1.5 hour at RT (catalog A02931-2)
WashTBS-0.1%Tween 3 times with 5 minutes each (catalog A02931-2)
DetectionECL (catalog A02931-2)
Section 2

What Is the Expected MATR3 Western Blot Band Size?

MATR3 is predicted at 94.6 kDa but observed at approximately 125 kDa; the cause of this difference is not established by the supplied evidence.

What am I looking at on my blot?
Band near 125 kDaMatches the empirical MATR3 band; confirm identity with antibody controls
Band near 95 kDaNear the 94.6 kDa predicted mass; identity requires confirmation
Several discrete bandsIsoforms 1 and 2 are possible contributors, but distinct migration is unproven
Stronger band in a nuclear matrix fractionConsistent with MATR3 localization to the nuclear matrix
💡Expected MATR3 appearanceMATR3 has a predicted mass of 94.6 kDa, while antibody QC shows a band at approximately 125 kDa in reducing whole-cell and tissue lysates; the cause of the difference is unestablished, so confirm band identity with antibody controls.
How each factor affects band size
UniProt predicted mass94.6 kDa is the sequence-based mass; the empirical band is approximately 125 kDa, with no established cause for the difference
Isoform 1Its individual mass and migration are not supplied
Isoform 2Its individual mass and migration are not supplied
Alternative splicing of isoforms 1 and 2Could affect band size, but distinct band positions are not established
Why is my band missing or off?
SituationLikely causeNext action
No band in lysateNuclear matrix MATR3 may be poorly recoveredCheck nuclear matrix extraction and a positive lysate
Band higher than expectedThe empirical MATR3 band is approximately 125 kDa despite a 94.6 kDa predicted mass; the cause is unestablishedCompare with the QC band and confirm identity with an independent antibody
Band lower than expectedAn isoform or degradation is possible, but its identity is unestablishedCheck sample integrity and confirm identity with an independent antibody
Multiple bandsIsoforms 1 and 2 or nonspecific binding are possibleCompare independent antibodies and check which bands track with MATR3 depletion
Weak or no signalNuclear matrix MATR3 may be poorly extractedVerify extraction and enrich the nuclear matrix fraction
Fragments below expected sizeSample degradation is possible; no fragment masses are suppliedCheck sample handling and compare fresh lysate with independent antibody detection

Sample controls for MATR3 Western blot

🧪HPA-IHC candidate guidance (verify in WB): For positive controls for MATR3 in Western blot, you can use adipose tissue lysate, which HPA scores high for expression.
Positive control: Adipose tissue (IHC candidate; verify WB)
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: No Not-detected tissue is listed, so use siRNA knockdown or a KO line as a negative control.

HPA tissue expression evidence for MATR3

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Higher expression tissues · candidate positive controls from IHC

TissueCell typeLevelEvidenceSource
Adipose tissue adipocytes High Protein (IHC) HPA →
Adrenal gland glandular cells High Protein (IHC) HPA →
Appendix glandular cells High Protein (IHC) HPA →
Bone marrow hematopoietic cells High Protein (IHC) HPA →
Breast adipocytes High Protein (IHC) HPA →

Lower expression tissues · IHC evidence, not confirmed WB-negative controls

TissueCell typeLevelEvidenceSource
Spleen cells in red pulp Medium Protein (IHC) HPA →
Adipose tissue adipocytes High Protein (IHC) HPA →
Adrenal gland glandular cells High Protein (IHC) HPA →
Appendix glandular cells High Protein (IHC) HPA →
Bone marrow hematopoietic cells High Protein (IHC) HPA →
Section 3

Advanced MATR3 Western Blot Tips

Deeper troubleshooting and optimisation questions for MATR3, answered from its protein features.

How should MATR3 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could MATR3 isoforms produce different bands?
Isoforms · UniProt lists two isoforms. In isoform 2, residues 1–304 of the canonical sequence are replaced by a 16-residue sequence, so the isoforms could migrate differently. Compare bands with antibodies recognizing a region shared by both isoforms, such as canonical residues 305–847.

Check its epitope against the isoform sequences. Isoform 2 replaces canonical residues 1–304, which contain several listed phosphosites, including Ser-4 and Tyr-158. A reagent targeting a site in that replaced region should not be assumed to recognize isoform 2. Site numbers here use UniProt canonical coordinates.
Which modifications matter when interpreting MATR3 bands?
PTM · UniProt lists 44 modified residues, including phosphorylation at Ser-4, Thr-150 and Tyr-158, and acetylation at Ser-2 and Lys-571. These are UniProt canonical-sequence coordinates; antibody or paper numbering may differ. The listed sites do not establish that a particular modification produces a visible band shift.
Does this guide establish induction of MATR3?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for MATR3?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02931-2 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should MATR3 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why might MATR3 appear near 125 kDa instead of 94.6 kDa?
Interpretation · 94.6 kDa is the predicted mass; the reported Western blot band is about 125 kDa. UniProt lists phosphorylation and acetylation sites, but their presence alone does not explain this difference. Use the observed band position as a reference and verify band identity independently.

MATR3 is annotated in the nucleus matrix. Keep sample preparation and fraction choice consistent across samples, then quantify the same validated band in each lane. If multiple bands are present, determine which represent MATR3 before combining their signals.

Isoform 2 is a candidate because it replaces canonical residues 1–304 with 16 residues. Band position alone cannot establish its identity. Check whether the antibody recognizes a sequence retained in isoform 2 and compare the candidate band with the canonical MATR3 band.

Not by itself. UniProt lists phosphorylation, acetylation and a Ubl-conjugation keyword, but the supplied features do not assign a modification to a band or specify a Ubl-conjugation site. Validate the band's identity before interpreting its migration as a modification.
Boster reagents

MATR3 Western Blot Antibodies

Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.

Real WB data Western blot analysis of MATR3 using anti-MATR3 antibody (A02931-2). Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human MCF-7 whole cell lysates, Lane 2: human SH-SY5Y whole cell lysates, Lane 3: human RT4 whole cell lysates, Lane 4: human HepG2 whole cell lysates, Lane 5: rat brain tissue lysates, Lane 6: mouse brain tissue lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-MATR3 antigen affinity purified polyclonal antibody (Catalog # A02931-2) at 0.25 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for MATR3 at approximately 125 kDa. The expected band size for MATR3 is at 95 kDa.
Anti-MATR3 Antibody Picoband®
Cat # A02931-2

The catalog reports one anti-MATR3 antibody, A02931-2, with reported human, mouse, and rat reactivity. Its Western blot image uses human cell and rat and mouse brain lysates; the reported band is approximately 125 kDa, versus an expected 95 kDa.

Which to pick: A02931-2 is the only listed option and has a Western blot image. Its caption documents human MCF-7, SH-SY5Y, RT4, and HepG2 cell lysates plus rat and mouse brain lysates, using antibody at 0.25 μg/mL.

Source: BosterBio MATR3 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.